Mark Purcell
Stock Analyst at Morgan Stanley
(1.33)
# 3,640
Out of 5,112 analysts
6
Total ratings
66.67%
Success rate
-5.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Purcell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNY Sanofi | Upgrades: Overweight | $56 → $58 | $47.99 | +20.86% | 2 | Sep 8, 2025 | |
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $135.27 | -15.72% | 1 | Jan 23, 2024 | |
| GSK GSK plc | Initiates: Equal-Weight | $44 | $48.29 | -8.88% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $90.61 | -6.19% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $47.61 | +152.05% | 1 | Jan 23, 2024 |
Sanofi
Sep 8, 2025
Upgrades: Overweight
Price Target: $56 → $58
Current: $47.99
Upside: +20.86%
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $135.27
Upside: -15.72%
GSK plc
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $48.29
Upside: -8.88%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $90.61
Upside: -6.19%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $47.61
Upside: +152.05%